WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: TP Kidney Transplant Astagraf XL Cmap 20131201, CMV may be Positive, Kidney Transplant Patients have Renal Function, Viral Status at Baseline includes HBV, Kidney Transplant Patients have HLA-DR Type, Calcineurin Inhibitor (CNI) may lead to Lymphoma, Kidney Transplant Patients receive Treatment, Renal Function assessed through analysis of Long Term Dialysis, BPAR calculate Event Rate Within First 24 weeks post transplantation, Exposure Related Toxicities such as Nephrotoxicity, Dosage Form administered Orally, Renal Function assessed through analysis of Creatinine Clearance, Calcineurin Inhibitor (CNI) are associated with Exposure Related Toxicities, EBV may be Positive, Calcineurin Inhibitor (CNI) may lead to Hyperlipidema, Demographics include Race, Graft Loss is the inverse of Graft Survival, Viral Status at Baseline includes HCV, Pharmacokinetic Response was linear From 1.5 mg to 10 mg (equivalent to doses upto 2.0 mg/kg) in Healthy Subjects, Gender can be Male, HCV may be Negative